RxDoctor Payments Data

Brent Webb, MD

Internal Medicine · Owensboro, KYNPI 1316406176

Payments from drug & device makers

$558in general payments, 2019–2025

Across 34 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$131
  • Novo Nordisk$94
  • Novartis$55
  • Exact Sciences$47
  • AbbVie$43
  • GSK$33
  • plus $155 from 7 others

What the payments were for

  • Food & beverage$558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$558 in reported general payments places this provider in the 55th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$67,839
Medicare patients
150
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide144$163,245
JardianceEmpagliflozin82$99,598
MounjaroTirzepatide48$61,493
ActemraTocilizumab13$61,356
FarxigaDapagliflozin Propanediol60$46,788
EliquisApixaban43$45,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$33,038
RybelsusSemaglutide11$25,630
TrulicityDulaglutide27$25,437
UbrelvyUbrogepant13$19,290
VascepaIcosapent Ethyl35$17,213
LinzessLinaclotide13$11,933
Repatha SureclickEvolocumab20$11,916
JanuviaSitagliptin Phosphate13$11,823
MyrbetriqMirabegron18$10,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$94$188,875155 claims
Lilly USA, LLCMounjaro, Trulicity$131$86,92975 claims
AstraZenecaFarxiga$32$46,78860 claims
PfizerEliquis$18$45,86043 claims
AbbVieUbrelvy, Linzess, Savella, Synthroid$43$38,22359 claims
GSKTrelegy Ellipta$33$33,03847 claims
Astellas Pharma US IncMyrbetriq$19$10,17618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →